GlassScriptPhysician profile
Amanda M Penegar
NPI 1962809160
$7,828.34
in general payments reported to CMS, 2019-2025
27 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,058 · 2022: $3,237 · 2023: $34.95 · 2024: $123 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.58 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,717.73 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,043.23 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $899.18 | 2021-2022 | |
| Janssen Biotech, INC. | $803.59 | 2021-2025 | Tremfya |
| Nestle Healthcare Nutrition INC. | $403.23 | 2021-2022 | |
| Vivus LLC | $335.08 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $307.60 | 2021-2022 | |
| Qol Medical, LLC | $295.79 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $240.04 | 2021-2022 | |
| Redhill Biopharma INC. | $223.29 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $190.53 | 2022 | |
| Genzyme Corporation | $174.44 | 2022-2025 | |
| Celgene Corporation | $171.29 | 2021-2022 | |
| Daiichi Sankyo INC. | $146.17 | 2021-2022 | |
| Pfizer INC. | $139.07 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $116.05 | 2021 | |
| Gilead Sciences, INC. | $106.13 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $105.85 | 2022-2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $104.58 | 2021-2022 | |
| Ardelyx, INC. | $70.58 | 2022 | |
| Ferring Pharmaceuticals INC. | $67.71 | 2021-2022 | |
| Organon LLC | $54.22 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.43 | 2022 | |
| Evoke Pharma, INC. | $29.96 | 2021 | |
| Pharmacosmos Therapeutics INC. | $16.10 | 2022 | |
| Boston Scientific Corporation | $14.77 | 2021 | |
| Avanos Medical | $14.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Penegar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.